The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

SCA Pharmaceuticals LLC (SCA) is announcing a recall of the following four lots of compounded product that was produced in its Windsor, CT, facility due to the potential for a foreign substance on a supplier-provided consumable to have been used during the compounding process:

Product Name	**NDC Number**	**Lot Number**	**Beyond Use Date**	**Quantity Shipped**	**Dates Distributed**
Fentanyl 2mcg/ml and Bupivacaine 0.125% in 0.9% Sodium Chloride 100 ml Bag	70004-0231-32	1222035837	22-Jul-22	384	04/18/2022 – 04/19/2022
Fentanyl 2mcg/ml and Bupivacaine 0.125% in 0.9% Sodium Chloride 100 ml Bag	70004-0231-32	1222035804	25-Jul-22	40	4/19/2022
Norepinephrine 8mg contains sulfites in 0.9% Sodium Chloride 250 ml Bag (32mcg/ml)	70004-0784-40	1222035815	10-Jul-22	120	04/19/2022 – 04/20/2022
Vancomycin HCl 1.5g added to 0.9% Sodium Chloride 500ml Bag (1500mg/ml)	70004-0924-44	1222035839	09-Aug-22	30	04/18/2022 – 04/19/2022

SCA has not received any adverse event reports and/or product complaints associated with the products being recalled.

Based on a Health Hazard Assessment, SCA has determined that there is a low risk of patient harm. However, because the origin of the foreign substance is currently unknown, SCA is recalling out of an abundance of caution while SCA and the supplier investigate the issue.

This recall is being carried out at the hospital level/direct account level with the knowledge and approval of the Food and Drug Administration.